ClinicalTrials.gg
CompletedNCT05443243PTHVarusUpdated Jul 5, 2022

Is a THA Stem in Varus a Risk Factor of Long-term Mechanical Complication

An observational study in Hip Arthritis, sponsored by University Hospital, Brest. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-05.

Sponsored by University Hospital, Brest · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
210
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the long-term survival as well as the functional and radiographic results of the rods in the alignment of the varus to the stems in the neutral alignment by comparing 2 groups of implanted Total Hip Arthroplasty. 1 group of stems implanted in varus position. 1 group of stems implanted in neutral position

Read the detailed description

ABSTRACT:

Introduction: Femoral stem positioning in the frontal plane has always been considered a fundamental criterion for implant survival and for functional and radiographic outcomes in total hip arthroplasty (THA). The impact of implanting cementless femoral stems in varus alignment on long-term mechanical complications remains poorly defined in the literature. The aim of our study is to compare long-term survivorship as well as functional and radiographic outcomes of stems in varus alignment to stems in neutral alignment.

Patients and Methods: This single center, multi-surgeon, retrospective case-control study will compare a group of 105 THA patients with varus stem alignment (VS) to a control group of 105 THA patients with neutral stem alignment (NS), operated in Brest center between January 2007 and December 2012. The primary outcome measure is implant survival. Secondary outcomes include functional outcomes: HHS, PMA, thigh pain, dislocation and hip ROM; and radiographic outcomes: radiolucency, Agora Roentgenography Assessment (ARA) score, osseointegration, heterotopic ossification, subsidence and stress shielding.

02

Conditions studied

  • Hip Arthritis
03

In context

Lead sponsor

University Hospital, Brest is the lead sponsor of 600 studies on the registry; 135 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who received a first-line PTH between 2007 and 2012,

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PTH rod implanted in varus,
  • Having X-rays and clinical data in their file
  • Within a period of less than 6 months
  • No opposition

Exclusion criteria

Exclusion Criteria:

  • PTH in a context of fracture of the femoral neck
  • PTH 2nd intention
  • Lost to sight
  • Patients who died within 6 months
  • Refusal to participate
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
210 participants (actual)
Patient registry
No

Groups and cohorts

  • Varus Stems

    Patients with a THA Stem implanted in Varus position

    Procedure: Total Hip Arthroplasty

  • Neutral stems

    Patients with a THA Stem implanted in Neutral position

    Procedure: Total Hip Arthroplasty

Interventions

  • ProcedureTotal Hip Arthroplasty

    Patient were operated, a Total hip arthroplasty was performed

06

What researchers measure

Primary outcomes

  1. Survival rate

    The main outcome measured was the survival of the implant

    Time frame: It was measured in October 2021

Secondary outcomes

  1. HHS

    Functional outcome : - The Harris Hip Score (HHS) \[26\] which assesses pain, function, deformity and range of motion (ROM) with a maximum score of 100

    Time frame: It was measured in October 2021

  2. PMA score :

    Functional outcome : which assesses pain, gait and mobility with a maximum score of 18

    Time frame: It was measured in October 2021

  3. Thigh pain

    Functional outcome : we measured the rate of patients experiencing pain at the level of the thigh

    Time frame: It was measured in October 2021

  4. Dislocation

    Functional outcome : hip disclocation rate over the follow up period

    Time frame: It was measured in October 2021

  5. Hip ROM

    Functional outcome : Hip range of motion in flexion, adduction, extension, abduction and rotations

    Time frame: It was measured in October 2021

  6. Radiolucency

    Radiographic outcome : - Radiolucency according to the Gruen/Callaghan zones

    Time frame: It was measured in October 2021

  7. Agora Roentgenography Assessment (ARA) score

    Radiographic outcome : - Agora Roentgenography Assessment (ARA) score for cementless femoral stem stability according to Epinette

    Time frame: It was measured in October 2021

  8. Osseointegration

    Radiographic outcome mesured was described in "Roentgenographic assessment of the biologic fixation of porous-surfaced femoral components" Engh CA, Massin P, Suthers KE"

    Time frame: It was measured in October 2021

  9. Heterotopic ossification

    Radiographic outcome : - Brooker classification of heterotopic ossification

    Time frame: t was measured in October 2021

  10. Subsidence

    Radiographic outcome : - Subsidence: considered significant if more than 5 mm between the immediate postoperative x-ray and the last follow-up x-ray. Subsidence was assessed by measuring the distance between the tip of the trochanter and the "shoulder" of the stem

    Time frame: t was measured in October 2021

  11. Stress shielding.

    Radiographic outcome : we measured the rate of patients with Xray showing stress shielding signs

    Time frame: t was measured in October 2021

07

Study locations

1 site
  • CHU de Brest
    Brest, 29609, France
08

References and documents

Publications

  • Batailler C, Fary C, Servien E, Lustig S. Influence of femoral broach shape on stem alignment using anterior approach for total hip arthroplasty: A radiologic comparative study of 3 different stems. PLoS One. 2018 Oct 5;13(10):e0204591. doi: 10.1371/journal.pone.0204591. eCollection 2018. PubMed 30289882 ↗
  • Murphy CG, Bonnin MP, Desbiolles AH, Carrillon Y, Asmall yi, Ukrainiant Si Selmi T. Varus will have varus; a radiological study to assess and predict varus stem placement in uncemented femoral stems. Hip Int. 2016 Nov 10;26(6):554-560. doi: 10.5301/hipint.5000412. Epub 2016 Oct 15. PubMed 27768218 ↗
  • Fottner A, Woiczinski M, Kistler M, Schroder C, Schmidutz TF, Jansson V, Schmidutz F. Varus malalignment of cementless hip stems provides sufficient primary stability but highly increases distal strain distribution. Clin Biomech (Bristol). 2018 Oct;58:14-20. doi: 10.1016/j.clinbiomech.2018.07.006. Epub 2018 Jul 5. PubMed 30005422 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05443243
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
May 13, 2022
Primary completion
May 16, 2022
Completion
May 16, 2022
Last update
Jul 5, 2022

Study contacts

Hoel Letissier, MD
principal investigator · CHU de Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion